AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie (NYSE:ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Wednesday reported third-quarter profit of $1.56 billion. On a per-share basis, the North Chicago, Illinois-based company ...

With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

“We’re really excited and proud to have the opportunity to support University of Chicago Medicine and the South Side ...

AbbVie says it needs to analyze the data to determine next steps. The North Chicago-based company’s shares fell as much as 12% at one point, the biggest decline in three years. The stock had been up ...

The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. Read More on ABBV: AbbVie NewsMORE Related Stocks Indices Commodities ...

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...

The new facility aims to give residents on the South Side better access to cancer care, while also attracting patients from ...

Analyst Carter Gould of Barclays maintained a Buy rating on AbbVie (ABBV – Research Report), retaining the price target of $212.00.